GLIADEL

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Metastatic Brain Cancer

Conditions

Metastatic Brain Cancer

Trial Timeline

Dec 12, 2007 → Dec 1, 2010

NCT ID

NCT00525590

About GLIADEL

GLIADEL is a phase 2 stage product being developed by Eisai for Metastatic Brain Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00525590. Target conditions include Metastatic Brain Cancer.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00525590	Phase 2	Completed	Dec 12, 2007	Dec 1, 2010	Metastatic Brain Cancer

Competing Products

20 competing products in Metastatic Brain Cancer

See all competitors

Product	Company	Stage	Hype Score
Autologous Mesothelin-specific TCR-T Cells + Cyclophosphamide + Fludarabine + Bendamustine	Lonza	Phase 1	30
Pemetrexed + Erlotinib + Pemetrexed + Erlotinib	Eli Lilly	Phase 2	52
SRF617 + etrumadenant + zimberelimab	Coherus BioSciences	Phase 2	44
ZN-c3 + Encorafenib + Cetuximab	Zentalis Pharmaceuticals	Phase 1	25
Abemaciclib	Eli Lilly	Pre-clinical	23
Ramucirumab + Placebo + Erlotinib + Gefitinib + Osimertinib	Eli Lilly	Phase 3	77
SYNB1891 + Atezolizumab	Synlogic	Phase 1	25
CT-P6 + Herceptin + Paclitaxel	Celltrion	Phase 3	77
CT-P6 + Herceptin + Paclitaxel	Celltrion	Phase 1/2	41
SPYK04	Chugai Pharmaceutical	Phase 1	33
LUNA18 + Cetuximab	Chugai Pharmaceutical	Phase 1	33
Induction therapy	Chugai Pharmaceutical	Phase 2	52
Trastuzumab + Pertuzumab + Docetaxel + Paclitaxel + Nab-paclitaxel + Vinorelbine + Eribulin + Capecitabine + Gemcitabine	Chugai Pharmaceutical	Phase 3	77
Paclitaxel + Bevacizumab + Letrozole + Anastrozole + Exemestane + Fulvestrant + Goserelin + leuprorelin	Chugai Pharmaceutical	Phase 2	52
bevacizumab + Paclitaxel	Chugai Pharmaceutical	Phase 2	52
Bevacizumab + 5-fluorouracil + Leucovorin calcium + Irinotecan hydrochloride + Oxaliplatin + Capecitabine	Chugai Pharmaceutical	Phase 2	52
GC33	Chugai Pharmaceutical	Phase 1	33
Gemcitabine and UFTE chemotherapy	Yuhan	Phase 2	52
Trastuzumab Deruxtecan + Cisplatin + Carboplatin + Pembrolizumab + Pemetrexed	Daiichi Sankyo	Phase 3	77
DS9051b	Daiichi Sankyo	Phase 1	33

Other Products from Eisai

MecobalaminApproved

MonteplaseApproved

E2020 + PlaceboApproved

Palonosetron 0.075 mg IV + Dexamethasone 10 mg IV + Promethazine 25 mg IVApproved

DonepezilApproved